Teva Pharmaceutical Industries Limited filed a current report on September 3, 2026, disclosing a material modification to the rights of security holders in connection with the planned termination of its American depositary share program and the direct listing of its ordinary shares on the New York Stock Exchange.
Key Highlights
- ADS program termination date: The ADS program is expected to terminate at the open of business (New York time) on September 14, 2026.
- One-for-one exchange: Each ADS will be cancelled and exchanged for one NYSE-listed ordinary share, described in the filing as "economically equivalent."
- Deposit agreement amended: On August 31, 2026, Teva executed Amendment No. 1 to its Second Amended and Restated Deposit Agreement, originally dated December 4, 2018, with Citibank, N.A. as depositary.
- Ordinary share par value: Each ordinary share carries a par value of NIS 0.10 per share.
- Signed by CFO: The filing was signed by Eli Kalif, Executive Vice President and Chief Financial Officer.
Teva Shifts from Depositary Receipts to Direct NYSE Ordinary Share Listing
According to the filing, Teva Pharmaceutical Industries Limited, an Israel-incorporated pharmaceutical company with principal executive offices in Parsippany, New Jersey, executed Amendment No. 1 to its existing deposit agreement on August 31, 2026. The amendment, made among the company, Citibank, N.A. as depositary, and all holders and beneficial owners of ADSs, establishes the specific mechanism by which outstanding ADSs will be mandatorily exchanged for ordinary shares when the program concludes.
The filing states that Teva had previously informed the depositary of its intent to list ordinary shares directly on the NYSE and instructed the depositary to terminate the ADS program. That prior disclosure appeared in Teva's Quarterly Report filed with the SEC on July 29, 2026. As a global generic and specialty pharmaceutical manufacturer, Teva's ordinary shares will, according to the filing, be listed on the NYSE under the ticker symbol TEVA, the same symbol previously used for the ADSs. The filing notes that "all outstanding ADSs will be cancelled in exchange for an equal number of economically equivalent NYSE-listed ordinary shares" effective at the open of business on September 14, 2026.
The filing further notes that the descriptions of Amendment No. 1 and the updated form of American depositary receipt are qualified in their entirety by reference to Exhibits 4.1 and 4.2 attached to the report. The company trades on NYSE:TEVA.
What Was Disclosed
Teva disclosed an amendment to its deposit agreement and the mechanism for mandatory ADS-to-ordinary-share exchange, with program termination set for September 14, 2026, resulting in each ADS holder receiving one NYSE-listed ordinary share in exchange.




Please wait processing your request...